Last reviewed · How we verify

DARATUMUMAB (DARZALEX®) — Competitive Intelligence Brief

DARATUMUMAB (DARZALEX®) (DARATUMUMAB (DARZALEX®)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD38-targeting monoclonal antibody. Area: Oncology.

marketed CD38-targeting monoclonal antibody CD38 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

DARATUMUMAB (DARZALEX®) (DARATUMUMAB (DARZALEX®)) — Hospices Civils de Lyon. Daratumumab is a monoclonal antibody that binds to CD38 on the surface of multiple myeloma cells, triggering their destruction through multiple immune mechanisms.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DARATUMUMAB (DARZALEX®) TARGET DARATUMUMAB (DARZALEX®) Hospices Civils de Lyon marketed CD38-targeting monoclonal antibody CD38
Darzalex Faspro daratumumab-and-hyaluronidase-fihj Pfizer marketed CD38-directed Cytolytic Antibody [EPC] CD38 2020-01-01
Darzalex daratumumab Johnson & Johnson marketed Monoclonal antibody CD38 2015-01-01
Daratumumab Hyaluronidase-fihj Daratumumab Hyaluronidase-fihj Memorial Sloan Kettering Cancer Center marketed CD38-targeting monoclonal antibody CD38
Daratumumab and corticosteroid treatment Daratumumab and corticosteroid treatment Institute of Hematology & Blood Diseases Hospital, China marketed Monoclonal antibody (CD38-targeting) combined with corticosteroid CD38
SARCLISA ISATUXIMAB-IRFC SANOFI AVENTIS US marketed CD38-directed Cytolytic Antibody [EPC] Lymphocyte differentiation antigen CD38
Darzalex Darzalex Shanghai Henlius Biotech marketed Lymphocyte differentiation antigen CD38

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD38-targeting monoclonal antibody class)

  1. Janssen Research & Development, LLC · 4 drugs in this class
  2. Charite University, Berlin, Germany · 1 drug in this class
  3. Hospices Civils de Lyon · 1 drug in this class
  4. Celltrion · 1 drug in this class
  5. Memorial Sloan Kettering Cancer Center · 1 drug in this class
  6. PrECOG, LLC. · 1 drug in this class
  7. Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DARATUMUMAB (DARZALEX®) — Competitive Intelligence Brief. https://druglandscape.com/ci/daratumumab-darzalex. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: